Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 14, 2022 04:23 ET | Source: Research and Markets

Worldwide Diagnostic Biochips Industry Report 2022: Emerging Microfluidic Biochip Fabrication Technologies Focusing on High-throughput Production

Dublin, Nov. 14, 2022 (GLOBE NEWSWIRE) -- The "Technological Innovations and Growth Opportunities in Diagnostic Biochips" report has been added to ResearchAndMarkets.com's offering. Biological...
November 10, 2022 21:00 ET | Source: Predicine

Predicine to Introduce PredicineCOMPLETE™, its Genome-Wide Liquid Biopsy Solution, at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

SILICON VALLEY, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Predicine, a global molecular insights company, announces the introduction of PredicineCOMPLETE™, the organization’s most comprehensive...
November 09, 2022 07:03 ET | Source: Research and Markets

Europe Infectious Respiratory Disease Diagnostics Market Report 2022: Rising Testing Rates Fueling Sector Growth

Dublin, Nov. 09, 2022 (GLOBE NEWSWIRE) -- The "Europe Infectious Respiratory Disease Diagnostics Market Size, Share & Industry Trends Analysis Report by Product Type, Application, Sample Type,...
November 08, 2022 16:05 ET | Source: Exagen Inc.

Exagen Inc. to Participate in Fourth Quarter Investor Conferences

SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that management will participate in the following fourth...
November 08, 2022 01:00 ET | Source: Biocartis NV

Persbericht Biocartis Group NV: Nieuwe Idylla™ EGFR studie toont reductie van tijd-tot-behandeling met 48% voor longkankerpatiënten

PERSBERICHT: 8 november 2022, 07:00 CET Nieuwe Idylla™ EGFR studie toont reductie van tijd-tot-behandeling met 48% voor longkankerpatiëntenIdylla™ EGFR Mutation Test (CE-IVD) leidt tot een...
November 08, 2022 01:00 ET | Source: Biocartis NV

Press release Biocartis Group NV: New Idylla™ EGFR Study Shows Reduction of Time-to-Treatment by 48% for Lung Cancer Patients

PRESS RELEASE: 8 November 2022, 07:00 CET New Idylla™ EGFR Study Shows Reduction of Time-to-Treatment by 48% for Lung Cancer PatientsIdylla™ EGFR Mutation Test (CE-IVD) leading to time-to-treatment...
November 07, 2022 08:53 ET | Source: Research and Markets

Global Companion Diagnostics Market Report 2022: Increasing Clinical Trials and Need for Next-Generation Sequencing to Drive Sector

Dublin, Nov. 07, 2022 (GLOBE NEWSWIRE) -- The "Global Companion Diagnostics Market, By Product and Service, By Technology & By Region- Forecast and Analysis 2022-28" report has been added to ...
November 04, 2022 08:00 ET | Source: ProPhase Labs, Inc.

ProPhase Labs to Host Third Quarter 2022 Financial Results Conference Call on Thursday, November 10, 2022 at 11:00 a.m. Eastern Time

GARDEN CITY, NY, Nov. 04, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, will hold a conference call on...
October 31, 2022 16:05 ET | Source: Exagen Inc.

Exagen to Announce Third Quarter 2022 Financial Results on November 14, 2022

SAN DIEGO, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended September 30, 2022,...
October 27, 2022 07:28 ET | Source: Research and Markets

Global Acute Cholecystitis Market Report 2022: Well-Populated Development Pipeline of Effective Drugs Bodes Well for Sector

Dublin, Oct. 27, 2022 (GLOBE NEWSWIRE) -- The "Global Acute Cholecystitis Market, By Type, By Cause (Gall Bladder Stones, Tumor, Bile Duct Blockage, Microbial Infection, Others) By Diagnostic...